Dyadic Common Stock Net 2010-2024 | DYAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dyadic common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dyadic common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$150.5B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$115.4B
Gilead Sciences (GILD)	$109.4B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$34.4B
Alnylam Pharmaceuticals (ALNY)	$30.2B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$22.6B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$14.3B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.6B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.9B
Bio-Techne Corp (TECH)	$10.5B
Sarepta Therapeutics (SRPT)	$10.2B
Exact Sciences (EXAS)	$10B
Exelixis (EXEL)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.3B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$7.5B
Repligen (RGEN)	$7.2B